Topical tacrolimus for repigmentation of vitiligo - 28/04/12
Doi : 10.1067/mjd.2002.126250
Pearl E. Grimes, MDa,b, Teresa Soriano, MDb, Marlene T. Dytoc, MD, PhDc*
Los Angeles, California, and Edmonton, Alberta, Canada
From the Vitiligo and Pigmentation Institute of Southern California,a and the Division of Dermatology, University of California, Los Angelesb; and the Division of Dermatology and Cutaneous Sciences, University of Alberta.c
Abstract |
We describe 6 patients with generalized vitiligo who responded to treatment with tacrolimus ointment. Moderate to excellent repigmentation was achieved in 5 patients. Although the number of cases in this noncontrolled, nonblinded series is small, tacrolimus ointment may be an efficacious and safe treatment option for vitiligo. (J Am Acad Dermatol 2002;47:789-91.)
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: None. |
| Disclosure: Dr Grimes is currently conducting a clinical trial using Protopic (tacrolimus) for Fujisawa Healthcare. |
 | *Dr Dytoc received a Frederick Kalz Bursary from the Canadian Dermatology Foundation to study with Dr Grimes. |
| Reprint requests: Pearl E. Grimes, MD, The Vitiligo and Pigmentation Institute of Southern California, 321 N Larchmont Blvd, Suite 609, Los Angeles, CA 90004. E-mail: pegrimesmd@earthlink.net. |
| ♢ | Published online September 23, 2002. |
© 2002
American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 47 - N° 5
P. 789-791 - novembre 2002 Retour au numéro
Article précédent
- Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder
- Thomas G. Salopeka, Sarvesh Logsettyb, Edward E. Tredgetb
- Follicular differentiation in basal cell carcinoma and the trend to designate benign or questionable lesions as malignant
- Ronald P. Rapini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?